nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A3—Melphalan—ovarian cancer	0.405	0.909	CbGbCtD
Amphetamine—L-Phenylalanine—Melphalan—ovarian cancer	0.314	1	CrCrCtD
Amphetamine—CYP2D6—Vinorelbine—ovarian cancer	0.0294	0.0659	CbGbCtD
Amphetamine—CYP2D6—Doxorubicin—ovarian cancer	0.0111	0.025	CbGbCtD
Amphetamine—TAAR1—female reproductive system—ovarian cancer	0.00402	0.067	CbGeAlD
Amphetamine—CARTPT—female reproductive system—ovarian cancer	0.00402	0.067	CbGeAlD
Amphetamine—CARTPT—testis—ovarian cancer	0.00324	0.0541	CbGeAlD
Amphetamine—CARTPT—lymph node—ovarian cancer	0.00235	0.0392	CbGeAlD
Amphetamine—SLC18A2—uterine cervix—ovarian cancer	0.00182	0.0304	CbGeAlD
Amphetamine—SLC22A3—myometrium—ovarian cancer	0.00167	0.0278	CbGeAlD
Amphetamine—SLC18A2—endometrium—ovarian cancer	0.00165	0.0275	CbGeAlD
Amphetamine—SLC22A3—embryo—ovarian cancer	0.0016	0.0267	CbGeAlD
Amphetamine—MAOB—myometrium—ovarian cancer	0.00154	0.0257	CbGeAlD
Amphetamine—SLC18A2—uterus—ovarian cancer	0.00152	0.0253	CbGeAlD
Amphetamine—MAOB—embryo—ovarian cancer	0.00148	0.0247	CbGeAlD
Amphetamine—SLC18A2—female reproductive system—ovarian cancer	0.00136	0.0228	CbGeAlD
Amphetamine—SLC22A3—uterine cervix—ovarian cancer	0.0013	0.0216	CbGeAlD
Amphetamine—SLC18A2—vagina—ovarian cancer	0.00123	0.0206	CbGeAlD
Amphetamine—SLC22A5—myometrium—ovarian cancer	0.00121	0.0202	CbGeAlD
Amphetamine—MAOB—uterine cervix—ovarian cancer	0.0012	0.02	CbGeAlD
Amphetamine—SLC22A3—endometrium—ovarian cancer	0.00117	0.0196	CbGeAlD
Amphetamine—MAOB—decidua—ovarian cancer	0.00114	0.0191	CbGeAlD
Amphetamine—CYP2A6—vagina—ovarian cancer	0.0011	0.0184	CbGeAlD
Amphetamine—SLC18A2—testis—ovarian cancer	0.0011	0.0184	CbGeAlD
Amphetamine—SLC22A3—gonad—ovarian cancer	0.00109	0.0181	CbGeAlD
Amphetamine—MAOB—endometrium—ovarian cancer	0.00109	0.0181	CbGeAlD
Amphetamine—SLC6A2—decidua—ovarian cancer	0.00106	0.0177	CbGeAlD
Amphetamine—MAOB—uterus—ovarian cancer	0.001	0.0167	CbGeAlD
Amphetamine—SLC22A3—female reproductive system—ovarian cancer	0.000972	0.0162	CbGeAlD
Amphetamine—SLC6A4—female reproductive system—ovarian cancer	0.000946	0.0158	CbGeAlD
Amphetamine—SLC22A5—uterine cervix—ovarian cancer	0.000943	0.0157	CbGeAlD
Amphetamine—Pseudoephedrine—IL2—ovarian cancer	0.000933	0.883	CrCbGaD
Amphetamine—SLC6A2—gonad—ovarian cancer	0.000932	0.0156	CbGeAlD
Amphetamine—MAOB—female reproductive system—ovarian cancer	0.000899	0.015	CbGeAlD
Amphetamine—SLC22A3—female gonad—ovarian cancer	0.000884	0.0147	CbGeAlD
Amphetamine—SLC22A3—vagina—ovarian cancer	0.000879	0.0147	CbGeAlD
Amphetamine—SLC22A5—endometrium—ovarian cancer	0.000853	0.0142	CbGeAlD
Amphetamine—SLC6A3—testis—ovarian cancer	0.000833	0.0139	CbGeAlD
Amphetamine—SLC6A2—female reproductive system—ovarian cancer	0.000833	0.0139	CbGeAlD
Amphetamine—MAOB—female gonad—ovarian cancer	0.000818	0.0136	CbGeAlD
Amphetamine—MAOB—vagina—ovarian cancer	0.000813	0.0136	CbGeAlD
Amphetamine—SLC18A2—lymph node—ovarian cancer	0.000798	0.0133	CbGeAlD
Amphetamine—SLC22A3—testis—ovarian cancer	0.000784	0.0131	CbGeAlD
Amphetamine—MAOB—testis—ovarian cancer	0.000726	0.0121	CbGeAlD
Amphetamine—SLC22A5—female reproductive system—ovarian cancer	0.000707	0.0118	CbGeAlD
Amphetamine—SLC6A2—testis—ovarian cancer	0.000672	0.0112	CbGeAlD
Amphetamine—SLC22A5—female gonad—ovarian cancer	0.000643	0.0107	CbGeAlD
Amphetamine—SLC22A5—vagina—ovarian cancer	0.000639	0.0107	CbGeAlD
Amphetamine—DRD2—testis—ovarian cancer	0.000612	0.0102	CbGeAlD
Amphetamine—SLC22A5—testis—ovarian cancer	0.00057	0.00951	CbGeAlD
Amphetamine—SLC22A3—lymph node—ovarian cancer	0.000569	0.00948	CbGeAlD
Amphetamine—MAOB—lymph node—ovarian cancer	0.000526	0.00877	CbGeAlD
Amphetamine—Decreased appetite—Chlorambucil—ovarian cancer	0.0005	0.00424	CcSEcCtD
Amphetamine—Infection—Melphalan—ovarian cancer	0.000498	0.00423	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000497	0.00422	CcSEcCtD
Amphetamine—Fatigue—Chlorambucil—ovarian cancer	0.000496	0.00421	CcSEcCtD
Amphetamine—Hyperhidrosis—Topotecan—ovarian cancer	0.000495	0.0042	CcSEcCtD
Amphetamine—Angioedema—Vinorelbine—ovarian cancer	0.000491	0.00416	CcSEcCtD
Amphetamine—Tachycardia—Melphalan—ovarian cancer	0.00049	0.00415	CcSEcCtD
Amphetamine—Anorexia—Topotecan—ovarian cancer	0.000488	0.00414	CcSEcCtD
Amphetamine—SLC6A2—lymph node—ovarian cancer	0.000487	0.00812	CbGeAlD
Amphetamine—Viral infection—Doxorubicin—ovarian cancer	0.000484	0.00411	CcSEcCtD
Amphetamine—Anorexia—Melphalan—ovarian cancer	0.000478	0.00406	CcSEcCtD
Amphetamine—Palpitations—Vinorelbine—ovarian cancer	0.000474	0.00403	CcSEcCtD
Amphetamine—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.000473	0.00401	CcSEcCtD
Amphetamine—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000471	0.00399	CcSEcCtD
Amphetamine—Weight decreased—Paclitaxel—ovarian cancer	0.000469	0.00398	CcSEcCtD
Amphetamine—Dyskinesia—Doxorubicin—ovarian cancer	0.000465	0.00395	CcSEcCtD
Amphetamine—Abdominal pain upper—Docetaxel—ovarian cancer	0.000464	0.00394	CcSEcCtD
Amphetamine—Hypertension—Vinorelbine—ovarian cancer	0.000464	0.00393	CcSEcCtD
Amphetamine—Depression—Paclitaxel—ovarian cancer	0.000461	0.00391	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.000458	0.00389	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.000458	0.00388	CcSEcCtD
Amphetamine—Urticaria—Chlorambucil—ovarian cancer	0.000457	0.00388	CcSEcCtD
Amphetamine—Chest pain—Vinorelbine—ovarian cancer	0.000457	0.00388	CcSEcCtD
Amphetamine—Dyspnoea—Topotecan—ovarian cancer	0.000457	0.00388	CcSEcCtD
Amphetamine—CYP2D6—female reproductive system—ovarian cancer	0.000456	0.0076	CbGeAlD
Amphetamine—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000456	0.00387	CcSEcCtD
Amphetamine—Abdominal pain—Chlorambucil—ovarian cancer	0.000455	0.00386	CcSEcCtD
Amphetamine—Body temperature increased—Chlorambucil—ovarian cancer	0.000455	0.00386	CcSEcCtD
Amphetamine—Myocardial infarction—Paclitaxel—ovarian cancer	0.000453	0.00384	CcSEcCtD
Amphetamine—Dyspepsia—Topotecan—ovarian cancer	0.000451	0.00383	CcSEcCtD
Amphetamine—Urinary tract infection—Paclitaxel—ovarian cancer	0.000449	0.00381	CcSEcCtD
Amphetamine—Dyspnoea—Melphalan—ovarian cancer	0.000447	0.00379	CcSEcCtD
Amphetamine—Decreased appetite—Topotecan—ovarian cancer	0.000445	0.00378	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000442	0.00375	CcSEcCtD
Amphetamine—Fatigue—Topotecan—ovarian cancer	0.000442	0.00375	CcSEcCtD
Amphetamine—Dyspepsia—Melphalan—ovarian cancer	0.000442	0.00375	CcSEcCtD
Amphetamine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000438	0.00372	CcSEcCtD
Amphetamine—Constipation—Topotecan—ovarian cancer	0.000438	0.00372	CcSEcCtD
Amphetamine—Decreased appetite—Melphalan—ovarian cancer	0.000436	0.0037	CcSEcCtD
Amphetamine—Infection—Vinorelbine—ovarian cancer	0.000435	0.00369	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000433	0.00367	CcSEcCtD
Amphetamine—Fatigue—Melphalan—ovarian cancer	0.000432	0.00367	CcSEcCtD
Amphetamine—Tachycardia—Vinorelbine—ovarian cancer	0.000428	0.00363	CcSEcCtD
Amphetamine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000424	0.0036	CcSEcCtD
Amphetamine—Gastrointestinal pain—Topotecan—ovarian cancer	0.000419	0.00355	CcSEcCtD
Amphetamine—Anorexia—Vinorelbine—ovarian cancer	0.000418	0.00354	CcSEcCtD
Amphetamine—CYP2D6—female gonad—ovarian cancer	0.000415	0.00692	CbGeAlD
Amphetamine—SLC22A5—lymph node—ovarian cancer	0.000413	0.00689	CbGeAlD
Amphetamine—Asthenia—Chlorambucil—ovarian cancer	0.000413	0.0035	CcSEcCtD
Amphetamine—Urticaria—Topotecan—ovarian cancer	0.000407	0.00345	CcSEcCtD
Amphetamine—Body temperature increased—Topotecan—ovarian cancer	0.000405	0.00344	CcSEcCtD
Amphetamine—Abdominal pain—Topotecan—ovarian cancer	0.000405	0.00344	CcSEcCtD
Amphetamine—Urticaria—Melphalan—ovarian cancer	0.000398	0.00338	CcSEcCtD
Amphetamine—Weight decreased—Docetaxel—ovarian cancer	0.000397	0.00337	CcSEcCtD
Amphetamine—Diarrhoea—Chlorambucil—ovarian cancer	0.000394	0.00334	CcSEcCtD
Amphetamine—Erythema multiforme—Paclitaxel—ovarian cancer	0.000392	0.00333	CcSEcCtD
Amphetamine—Dyspnoea—Vinorelbine—ovarian cancer	0.000391	0.00332	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.000388	0.0033	CcSEcCtD
Amphetamine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000386	0.00328	CcSEcCtD
Amphetamine—Myocardial infarction—Docetaxel—ovarian cancer	0.000384	0.00326	CcSEcCtD
Amphetamine—Decreased appetite—Vinorelbine—ovarian cancer	0.000381	0.00323	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000378	0.00321	CcSEcCtD
Amphetamine—Fatigue—Vinorelbine—ovarian cancer	0.000378	0.00321	CcSEcCtD
Amphetamine—Hypersensitivity—Topotecan—ovarian cancer	0.000377	0.0032	CcSEcCtD
Amphetamine—Constipation—Vinorelbine—ovarian cancer	0.000375	0.00318	CcSEcCtD
Amphetamine—Hypersensitivity—Melphalan—ovarian cancer	0.00037	0.00314	CcSEcCtD
Amphetamine—CYP2D6—testis—ovarian cancer	0.000368	0.00614	CbGeAlD
Amphetamine—Asthenia—Topotecan—ovarian cancer	0.000368	0.00312	CcSEcCtD
Amphetamine—Vomiting—Chlorambucil—ovarian cancer	0.000366	0.0031	CcSEcCtD
Amphetamine—Asthenia—Melphalan—ovarian cancer	0.00036	0.00305	CcSEcCtD
Amphetamine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000358	0.00304	CcSEcCtD
Amphetamine—Tension—Paclitaxel—ovarian cancer	0.000354	0.00301	CcSEcCtD
Amphetamine—Nervousness—Paclitaxel—ovarian cancer	0.000351	0.00298	CcSEcCtD
Amphetamine—Diarrhoea—Topotecan—ovarian cancer	0.00035	0.00297	CcSEcCtD
Amphetamine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00035	0.00297	CcSEcCtD
Amphetamine—Urticaria—Vinorelbine—ovarian cancer	0.000348	0.00295	CcSEcCtD
Amphetamine—Body temperature increased—Vinorelbine—ovarian cancer	0.000346	0.00294	CcSEcCtD
Amphetamine—Abdominal pain—Vinorelbine—ovarian cancer	0.000346	0.00294	CcSEcCtD
Amphetamine—Diarrhoea—Melphalan—ovarian cancer	0.000343	0.00291	CcSEcCtD
Amphetamine—Nausea—Chlorambucil—ovarian cancer	0.000342	0.0029	CcSEcCtD
Amphetamine—Dizziness—Topotecan—ovarian cancer	0.000339	0.00287	CcSEcCtD
Amphetamine—Tremor—Paclitaxel—ovarian cancer	0.000338	0.00287	CcSEcCtD
Amphetamine—Affect lability—Epirubicin—ovarian cancer	0.000337	0.00286	CcSEcCtD
Amphetamine—Erythema multiforme—Docetaxel—ovarian cancer	0.000332	0.00282	CcSEcCtD
Amphetamine—Agitation—Paclitaxel—ovarian cancer	0.000332	0.00282	CcSEcCtD
Amphetamine—Angioedema—Paclitaxel—ovarian cancer	0.00033	0.0028	CcSEcCtD
Amphetamine—Vomiting—Topotecan—ovarian cancer	0.000326	0.00276	CcSEcCtD
Amphetamine—Mood swings—Epirubicin—ovarian cancer	0.000325	0.00276	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000324	0.00275	CcSEcCtD
Amphetamine—Rash—Topotecan—ovarian cancer	0.000323	0.00274	CcSEcCtD
Amphetamine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000323	0.00274	CcSEcCtD
Amphetamine—Dermatitis—Topotecan—ovarian cancer	0.000323	0.00274	CcSEcCtD
Amphetamine—Headache—Topotecan—ovarian cancer	0.000321	0.00272	CcSEcCtD
Amphetamine—Palpitations—Paclitaxel—ovarian cancer	0.000319	0.00271	CcSEcCtD
Amphetamine—Vomiting—Melphalan—ovarian cancer	0.000319	0.00271	CcSEcCtD
Amphetamine—Rash—Melphalan—ovarian cancer	0.000316	0.00268	CcSEcCtD
Amphetamine—Dermatitis—Melphalan—ovarian cancer	0.000316	0.00268	CcSEcCtD
Amphetamine—Asthenia—Vinorelbine—ovarian cancer	0.000314	0.00267	CcSEcCtD
Amphetamine—Abdominal pain upper—Epirubicin—ovarian cancer	0.000313	0.00266	CcSEcCtD
Amphetamine—Convulsion—Paclitaxel—ovarian cancer	0.000313	0.00266	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—ovarian cancer	0.000312	0.00265	CcSEcCtD
Amphetamine—Hypertension—Paclitaxel—ovarian cancer	0.000312	0.00265	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000309	0.00262	CcSEcCtD
Amphetamine—Chest pain—Paclitaxel—ovarian cancer	0.000307	0.00261	CcSEcCtD
Amphetamine—Anxiety—Paclitaxel—ovarian cancer	0.000306	0.0026	CcSEcCtD
Amphetamine—Nausea—Topotecan—ovarian cancer	0.000304	0.00258	CcSEcCtD
Amphetamine—Dry mouth—Paclitaxel—ovarian cancer	0.000301	0.00255	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—ovarian cancer	0.000301	0.00255	CcSEcCtD
Amphetamine—Diarrhoea—Vinorelbine—ovarian cancer	0.0003	0.00254	CcSEcCtD
Amphetamine—Nausea—Melphalan—ovarian cancer	0.000298	0.00253	CcSEcCtD
Amphetamine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000295	0.0025	CcSEcCtD
Amphetamine—Infection—Paclitaxel—ovarian cancer	0.000293	0.00248	CcSEcCtD
Amphetamine—Dizziness—Vinorelbine—ovarian cancer	0.00029	0.00246	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—ovarian cancer	0.00029	0.00246	CcSEcCtD
Amphetamine—Tachycardia—Paclitaxel—ovarian cancer	0.000288	0.00244	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000286	0.00242	CcSEcCtD
Amphetamine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000285	0.00242	CcSEcCtD
Amphetamine—Anorexia—Paclitaxel—ovarian cancer	0.000281	0.00238	CcSEcCtD
Amphetamine—Vomiting—Vinorelbine—ovarian cancer	0.000279	0.00236	CcSEcCtD
Amphetamine—Rash—Vinorelbine—ovarian cancer	0.000276	0.00234	CcSEcCtD
Amphetamine—Dermatitis—Vinorelbine—ovarian cancer	0.000276	0.00234	CcSEcCtD
Amphetamine—Headache—Vinorelbine—ovarian cancer	0.000275	0.00233	CcSEcCtD
Amphetamine—Palpitations—Docetaxel—ovarian cancer	0.000271	0.0023	CcSEcCtD
Amphetamine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00027	0.0023	CcSEcCtD
Amphetamine—Weight decreased—Epirubicin—ovarian cancer	0.000268	0.00227	CcSEcCtD
Amphetamine—Insomnia—Paclitaxel—ovarian cancer	0.000267	0.00226	CcSEcCtD
Amphetamine—Convulsion—Docetaxel—ovarian cancer	0.000265	0.00225	CcSEcCtD
Amphetamine—Hypertension—Docetaxel—ovarian cancer	0.000264	0.00224	CcSEcCtD
Amphetamine—Dyspnoea—Paclitaxel—ovarian cancer	0.000263	0.00223	CcSEcCtD
Amphetamine—Somnolence—Paclitaxel—ovarian cancer	0.000262	0.00222	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000262	0.00222	CcSEcCtD
Amphetamine—Chest pain—Docetaxel—ovarian cancer	0.000261	0.00221	CcSEcCtD
Amphetamine—Nausea—Vinorelbine—ovarian cancer	0.00026	0.00221	CcSEcCtD
Amphetamine—Dyspepsia—Paclitaxel—ovarian cancer	0.000259	0.0022	CcSEcCtD
Amphetamine—Urinary tract infection—Epirubicin—ovarian cancer	0.000257	0.00218	CcSEcCtD
Amphetamine—Decreased appetite—Paclitaxel—ovarian cancer	0.000256	0.00217	CcSEcCtD
Amphetamine—Dry mouth—Docetaxel—ovarian cancer	0.000255	0.00216	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000254	0.00216	CcSEcCtD
Amphetamine—Fatigue—Paclitaxel—ovarian cancer	0.000254	0.00216	CcSEcCtD
Amphetamine—Sweating—Epirubicin—ovarian cancer	0.000253	0.00215	CcSEcCtD
Amphetamine—Constipation—Paclitaxel—ovarian cancer	0.000252	0.00214	CcSEcCtD
Amphetamine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.00025	0.00212	CcSEcCtD
Amphetamine—Anaphylactic shock—Docetaxel—ovarian cancer	0.00025	0.00212	CcSEcCtD
Amphetamine—Infection—Docetaxel—ovarian cancer	0.000248	0.00211	CcSEcCtD
Amphetamine—Weight decreased—Doxorubicin—ovarian cancer	0.000248	0.0021	CcSEcCtD
Amphetamine—Tachycardia—Docetaxel—ovarian cancer	0.000244	0.00207	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000242	0.00206	CcSEcCtD
Amphetamine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000241	0.00205	CcSEcCtD
Amphetamine—Anorexia—Docetaxel—ovarian cancer	0.000238	0.00202	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000238	0.00202	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—ovarian cancer	0.000234	0.00199	CcSEcCtD
Amphetamine—Urticaria—Paclitaxel—ovarian cancer	0.000234	0.00199	CcSEcCtD
Amphetamine—Body temperature increased—Paclitaxel—ovarian cancer	0.000233	0.00198	CcSEcCtD
Amphetamine—Abdominal pain—Paclitaxel—ovarian cancer	0.000233	0.00198	CcSEcCtD
Amphetamine—Insomnia—Docetaxel—ovarian cancer	0.000226	0.00192	CcSEcCtD
Amphetamine—Erythema multiforme—Epirubicin—ovarian cancer	0.000224	0.0019	CcSEcCtD
Amphetamine—Dyspnoea—Docetaxel—ovarian cancer	0.000223	0.00189	CcSEcCtD
Amphetamine—Somnolence—Docetaxel—ovarian cancer	0.000222	0.00188	CcSEcCtD
Amphetamine—Dyspepsia—Docetaxel—ovarian cancer	0.00022	0.00187	CcSEcCtD
Amphetamine—Decreased appetite—Docetaxel—ovarian cancer	0.000217	0.00184	CcSEcCtD
Amphetamine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000217	0.00184	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000216	0.00183	CcSEcCtD
Amphetamine—Fatigue—Docetaxel—ovarian cancer	0.000215	0.00183	CcSEcCtD
Amphetamine—Constipation—Docetaxel—ovarian cancer	0.000214	0.00181	CcSEcCtD
Amphetamine—Asthenia—Paclitaxel—ovarian cancer	0.000211	0.00179	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—ovarian cancer	0.000207	0.00176	CcSEcCtD
Amphetamine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000204	0.00173	CcSEcCtD
Amphetamine—Tension—Epirubicin—ovarian cancer	0.000203	0.00172	CcSEcCtD
Amphetamine—Diarrhoea—Paclitaxel—ovarian cancer	0.000202	0.00171	CcSEcCtD
Amphetamine—Nervousness—Epirubicin—ovarian cancer	0.000201	0.0017	CcSEcCtD
Amphetamine—Body temperature increased—Docetaxel—ovarian cancer	0.000197	0.00168	CcSEcCtD
Amphetamine—Abdominal pain—Docetaxel—ovarian cancer	0.000197	0.00168	CcSEcCtD
Amphetamine—Dizziness—Paclitaxel—ovarian cancer	0.000195	0.00165	CcSEcCtD
Amphetamine—Agitation—Epirubicin—ovarian cancer	0.00019	0.00161	CcSEcCtD
Amphetamine—Tension—Doxorubicin—ovarian cancer	0.000187	0.00159	CcSEcCtD
Amphetamine—Vomiting—Paclitaxel—ovarian cancer	0.000187	0.00159	CcSEcCtD
Amphetamine—Rash—Paclitaxel—ovarian cancer	0.000186	0.00158	CcSEcCtD
Amphetamine—Dermatitis—Paclitaxel—ovarian cancer	0.000186	0.00158	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—ovarian cancer	0.000186	0.00157	CcSEcCtD
Amphetamine—Headache—Paclitaxel—ovarian cancer	0.000185	0.00157	CcSEcCtD
Amphetamine—Hypersensitivity—Docetaxel—ovarian cancer	0.000184	0.00156	CcSEcCtD
Amphetamine—Palpitations—Epirubicin—ovarian cancer	0.000182	0.00155	CcSEcCtD
Amphetamine—Asthenia—Docetaxel—ovarian cancer	0.000179	0.00152	CcSEcCtD
Amphetamine—Convulsion—Epirubicin—ovarian cancer	0.000179	0.00152	CcSEcCtD
Amphetamine—Hypertension—Epirubicin—ovarian cancer	0.000178	0.00151	CcSEcCtD
Amphetamine—Chest pain—Epirubicin—ovarian cancer	0.000176	0.00149	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—ovarian cancer	0.000176	0.00149	CcSEcCtD
Amphetamine—Anxiety—Epirubicin—ovarian cancer	0.000175	0.00149	CcSEcCtD
Amphetamine—Nausea—Paclitaxel—ovarian cancer	0.000175	0.00149	CcSEcCtD
Amphetamine—Dry mouth—Epirubicin—ovarian cancer	0.000172	0.00146	CcSEcCtD
Amphetamine—Diarrhoea—Docetaxel—ovarian cancer	0.000171	0.00145	CcSEcCtD
Amphetamine—Palpitations—Doxorubicin—ovarian cancer	0.000169	0.00143	CcSEcCtD
Amphetamine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000169	0.00143	CcSEcCtD
Amphetamine—Infection—Epirubicin—ovarian cancer	0.000167	0.00142	CcSEcCtD
Amphetamine—Convulsion—Doxorubicin—ovarian cancer	0.000166	0.0014	CcSEcCtD
Amphetamine—Dizziness—Docetaxel—ovarian cancer	0.000165	0.0014	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—ovarian cancer	0.000165	0.0014	CcSEcCtD
Amphetamine—Tachycardia—Epirubicin—ovarian cancer	0.000164	0.0014	CcSEcCtD
Amphetamine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000163	0.00138	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—ovarian cancer	0.000163	0.00138	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—ovarian cancer	0.000162	0.00138	CcSEcCtD
Amphetamine—Anorexia—Epirubicin—ovarian cancer	0.000161	0.00136	CcSEcCtD
Amphetamine—Dry mouth—Doxorubicin—ovarian cancer	0.000159	0.00135	CcSEcCtD
Amphetamine—Vomiting—Docetaxel—ovarian cancer	0.000159	0.00135	CcSEcCtD
Amphetamine—Rash—Docetaxel—ovarian cancer	0.000158	0.00134	CcSEcCtD
Amphetamine—Dermatitis—Docetaxel—ovarian cancer	0.000157	0.00134	CcSEcCtD
Amphetamine—Headache—Docetaxel—ovarian cancer	0.000157	0.00133	CcSEcCtD
Amphetamine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000156	0.00132	CcSEcCtD
Amphetamine—Infection—Doxorubicin—ovarian cancer	0.000155	0.00131	CcSEcCtD
Amphetamine—Insomnia—Epirubicin—ovarian cancer	0.000152	0.00129	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—ovarian cancer	0.000152	0.00129	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000151	0.00128	CcSEcCtD
Amphetamine—Dyspnoea—Epirubicin—ovarian cancer	0.00015	0.00127	CcSEcCtD
Amphetamine—Somnolence—Epirubicin—ovarian cancer	0.00015	0.00127	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—ovarian cancer	0.000149	0.00126	CcSEcCtD
Amphetamine—Nausea—Docetaxel—ovarian cancer	0.000148	0.00126	CcSEcCtD
Amphetamine—Dyspepsia—Epirubicin—ovarian cancer	0.000148	0.00126	CcSEcCtD
Amphetamine—Decreased appetite—Epirubicin—ovarian cancer	0.000146	0.00124	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000145	0.00123	CcSEcCtD
Amphetamine—Fatigue—Epirubicin—ovarian cancer	0.000145	0.00123	CcSEcCtD
Amphetamine—Constipation—Epirubicin—ovarian cancer	0.000144	0.00122	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—ovarian cancer	0.000141	0.0012	CcSEcCtD
Amphetamine—Dyspnoea—Doxorubicin—ovarian cancer	0.000139	0.00118	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—ovarian cancer	0.000139	0.00118	CcSEcCtD
Amphetamine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000138	0.00117	CcSEcCtD
Amphetamine—Dyspepsia—Doxorubicin—ovarian cancer	0.000137	0.00116	CcSEcCtD
Amphetamine—Decreased appetite—Doxorubicin—ovarian cancer	0.000136	0.00115	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000135	0.00114	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—ovarian cancer	0.000134	0.00114	CcSEcCtD
Amphetamine—Urticaria—Epirubicin—ovarian cancer	0.000134	0.00114	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—ovarian cancer	0.000133	0.00113	CcSEcCtD
Amphetamine—Body temperature increased—Epirubicin—ovarian cancer	0.000133	0.00113	CcSEcCtD
Amphetamine—Abdominal pain—Epirubicin—ovarian cancer	0.000133	0.00113	CcSEcCtD
Amphetamine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000127	0.00108	CcSEcCtD
Amphetamine—Hypersensitivity—Epirubicin—ovarian cancer	0.000124	0.00105	CcSEcCtD
Amphetamine—Selegiline—ABCB1—ovarian cancer	0.000124	0.117	CrCbGaD
Amphetamine—Urticaria—Doxorubicin—ovarian cancer	0.000124	0.00105	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—ovarian cancer	0.000123	0.00105	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—ovarian cancer	0.000123	0.00105	CcSEcCtD
Amphetamine—Asthenia—Epirubicin—ovarian cancer	0.000121	0.00103	CcSEcCtD
Amphetamine—Diarrhoea—Epirubicin—ovarian cancer	0.000115	0.000978	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000115	0.000975	CcSEcCtD
Amphetamine—Asthenia—Doxorubicin—ovarian cancer	0.000112	0.000949	CcSEcCtD
Amphetamine—Dizziness—Epirubicin—ovarian cancer	0.000111	0.000946	CcSEcCtD
Amphetamine—Vomiting—Epirubicin—ovarian cancer	0.000107	0.000909	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—ovarian cancer	0.000107	0.000905	CcSEcCtD
Amphetamine—Rash—Epirubicin—ovarian cancer	0.000106	0.000902	CcSEcCtD
Amphetamine—Dermatitis—Epirubicin—ovarian cancer	0.000106	0.000901	CcSEcCtD
Amphetamine—Headache—Epirubicin—ovarian cancer	0.000106	0.000896	CcSEcCtD
Amphetamine—Dizziness—Doxorubicin—ovarian cancer	0.000103	0.000875	CcSEcCtD
Amphetamine—Nausea—Epirubicin—ovarian cancer	0.0001	0.000849	CcSEcCtD
Amphetamine—Vomiting—Doxorubicin—ovarian cancer	9.91e-05	0.000841	CcSEcCtD
Amphetamine—Rash—Doxorubicin—ovarian cancer	9.83e-05	0.000834	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—ovarian cancer	9.82e-05	0.000833	CcSEcCtD
Amphetamine—Headache—Doxorubicin—ovarian cancer	9.77e-05	0.000829	CcSEcCtD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—AQP3—ovarian cancer	9.45e-05	0.00152	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	9.4e-05	0.00151	CbGpPWpGaD
Amphetamine—Nausea—Doxorubicin—ovarian cancer	9.26e-05	0.000786	CcSEcCtD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	9.08e-05	0.00146	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HDAC6—ovarian cancer	9.08e-05	0.00146	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ATP7B—ovarian cancer	9.06e-05	0.00146	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PPP2R1A—ovarian cancer	8.96e-05	0.00144	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CXCL8—ovarian cancer	8.6e-05	0.00139	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYTB—ovarian cancer	8.16e-05	0.00132	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.08e-05	0.0013	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—YAP1—ovarian cancer	8.04e-05	0.00129	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	8.02e-05	0.00129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—XIAP—ovarian cancer	7.87e-05	0.00127	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.74e-05	0.00125	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SMARCA4—ovarian cancer	7.67e-05	0.00124	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	7.52e-05	0.00121	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EREG—ovarian cancer	7.49e-05	0.00121	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CASP3—ovarian cancer	7.2e-05	0.00116	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TUBB3—ovarian cancer	7.16e-05	0.00115	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPP1CC—ovarian cancer	7.14e-05	0.00115	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—BRIP1—ovarian cancer	7.14e-05	0.00115	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PGR—ovarian cancer	7.02e-05	0.00113	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TYMS—ovarian cancer	6.95e-05	0.00112	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	6.94e-05	0.00112	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.93e-05	0.00112	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	6.91e-05	0.00111	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYTB—ovarian cancer	6.91e-05	0.00111	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.69e-05	0.00108	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	6.67e-05	0.00107	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PIK3CG—ovarian cancer	6.6e-05	0.00106	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PARP1—ovarian cancer	6.52e-05	0.00105	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6ST—ovarian cancer	6.24e-05	0.00101	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NME2—ovarian cancer	6.17e-05	0.000994	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	6.11e-05	0.000985	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	6.11e-05	0.000984	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPP1CC—ovarian cancer	6.04e-05	0.000972	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—BRIP1—ovarian cancer	6.04e-05	0.000972	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CG—ovarian cancer	6e-05	0.000966	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PIK3CD—ovarian cancer	5.8e-05	0.000935	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	5.76e-05	0.000927	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	5.68e-05	0.000914	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	5.6e-05	0.000902	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—PTEN—ovarian cancer	5.52e-05	0.000889	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HSD17B6—ovarian cancer	5.42e-05	0.000874	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.39e-05	0.000869	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PPP2R1A—ovarian cancer	5.29e-05	0.000852	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.29e-05	0.000851	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CD—ovarian cancer	5.27e-05	0.000849	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.27e-05	0.000849	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.21e-05	0.000839	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PIK3CB—ovarian cancer	5.06e-05	0.000815	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL8—ovarian cancer	4.86e-05	0.000783	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—YAP1—ovarian cancer	4.79e-05	0.000771	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.78e-05	0.00077	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL2—ovarian cancer	4.65e-05	0.000748	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—ovarian cancer	4.62e-05	0.000745	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.61e-05	0.000743	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DLC1—ovarian cancer	4.61e-05	0.000743	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CB—ovarian cancer	4.59e-05	0.00074	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL8—ovarian cancer	4.41e-05	0.000711	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—MAPK1—ovarian cancer	4.41e-05	0.000711	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—ovarian cancer	4.22e-05	0.00068	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL2—ovarian cancer	4.22e-05	0.00068	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TERT—ovarian cancer	4.2e-05	0.000677	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.11e-05	0.000663	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—YAP1—ovarian cancer	4.05e-05	0.000652	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYTB—ovarian cancer	3.98e-05	0.000641	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—FASN—ovarian cancer	3.9e-05	0.000628	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CAV1—ovarian cancer	3.89e-05	0.000626	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC5A5—ovarian cancer	3.84e-05	0.000618	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—ovarian cancer	3.77e-05	0.000607	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BCL9—ovarian cancer	3.76e-05	0.000606	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ESR1—ovarian cancer	3.75e-05	0.000604	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC2A1—ovarian cancer	3.71e-05	0.000597	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6ST—ovarian cancer	3.69e-05	0.000594	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.64e-05	0.000587	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP1B1—ovarian cancer	3.55e-05	0.000572	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CG—ovarian cancer	3.54e-05	0.000571	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APC—ovarian cancer	3.54e-05	0.000571	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—NRAS—ovarian cancer	3.54e-05	0.000571	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—HRAS—ovarian cancer	3.54e-05	0.00057	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPP1CC—ovarian cancer	3.48e-05	0.00056	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—BRIP1—ovarian cancer	3.48e-05	0.00056	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NME2—ovarian cancer	3.46e-05	0.000557	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—ovarian cancer	3.45e-05	0.000555	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.43e-05	0.000553	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—MAPK3—ovarian cancer	3.39e-05	0.000546	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PTEN—ovarian cancer	3.38e-05	0.000544	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—ovarian cancer	3.31e-05	0.000534	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—FASN—ovarian cancer	3.3e-05	0.000532	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC5A5—ovarian cancer	3.25e-05	0.000523	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—MAPK1—ovarian cancer	3.23e-05	0.00052	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—EGFR—ovarian cancer	3.23e-05	0.00052	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPP2R1A—ovarian cancer	3.15e-05	0.000508	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC2A1—ovarian cancer	3.14e-05	0.000505	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CD—ovarian cancer	3.11e-05	0.000502	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PIK3CA—ovarian cancer	3.08e-05	0.000497	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—KRAS—ovarian cancer	3.05e-05	0.000491	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP1B1—ovarian cancer	3.01e-05	0.000484	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DOK1—ovarian cancer	2.97e-05	0.000479	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ABCB1—ovarian cancer	2.93e-05	0.000471	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TYMS—ovarian cancer	2.87e-05	0.000463	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CA—ovarian cancer	2.8e-05	0.000451	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PPP1CC—ovarian cancer	2.79e-05	0.00045	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.76e-05	0.000444	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB2—ovarian cancer	2.75e-05	0.000443	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CB—ovarian cancer	2.71e-05	0.000437	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MTOR—ovarian cancer	2.71e-05	0.000437	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPP2R1A—ovarian cancer	2.67e-05	0.000429	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	2.63e-05	0.000424	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—MAPK1—ovarian cancer	2.63e-05	0.000424	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—ovarian cancer	2.61e-05	0.00042	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—ovarian cancer	2.59e-05	0.000417	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1B—ovarian cancer	2.55e-05	0.00041	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—ovarian cancer	2.52e-05	0.000406	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP3—ovarian cancer	2.5e-05	0.000402	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2—ovarian cancer	2.49e-05	0.000401	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—ovarian cancer	2.48e-05	0.000399	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCB1—ovarian cancer	2.48e-05	0.000399	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TYMS—ovarian cancer	2.43e-05	0.000392	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCND1—ovarian cancer	2.43e-05	0.000391	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CTNNB1—ovarian cancer	2.41e-05	0.000388	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—ovarian cancer	2.36e-05	0.00038	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTEN—ovarian cancer	2.34e-05	0.000378	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—YAP1—ovarian cancer	2.33e-05	0.000376	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CAV1—ovarian cancer	2.32e-05	0.000373	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—ovarian cancer	2.3e-05	0.000371	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—ovarian cancer	2.29e-05	0.000369	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYTB—ovarian cancer	2.23e-05	0.000359	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—ovarian cancer	2.12e-05	0.000341	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC6—ovarian cancer	2.12e-05	0.000341	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—ovarian cancer	2.11e-05	0.00034	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CG—ovarian cancer	2.11e-05	0.00034	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—ovarian cancer	2.11e-05	0.00034	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—ovarian cancer	2.1e-05	0.000338	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—ovarian cancer	2.09e-05	0.000337	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PPP2R1A—ovarian cancer	2.09e-05	0.000337	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—ovarian cancer	2.01e-05	0.000323	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK3—ovarian cancer	2e-05	0.000323	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CAV1—ovarian cancer	1.96e-05	0.000316	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPP1CC—ovarian cancer	1.95e-05	0.000314	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—BRIP1—ovarian cancer	1.95e-05	0.000314	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—ovarian cancer	1.95e-05	0.000314	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK1—ovarian cancer	1.91e-05	0.000307	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—ovarian cancer	1.91e-05	0.000307	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—FASN—ovarian cancer	1.9e-05	0.000306	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—YAP1—ovarian cancer	1.87e-05	0.000302	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC5A5—ovarian cancer	1.87e-05	0.000301	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CD—ovarian cancer	1.85e-05	0.000299	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—XIAP—ovarian cancer	1.84e-05	0.000296	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC2A1—ovarian cancer	1.81e-05	0.000291	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—ovarian cancer	1.8e-05	0.00029	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMARCA4—ovarian cancer	1.79e-05	0.000288	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CG—ovarian cancer	1.78e-05	0.000287	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EREG—ovarian cancer	1.75e-05	0.000281	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1B1—ovarian cancer	1.73e-05	0.000279	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CA—ovarian cancer	1.65e-05	0.000266	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PGR—ovarian cancer	1.64e-05	0.000264	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CB—ovarian cancer	1.62e-05	0.00026	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—ovarian cancer	1.6e-05	0.000258	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CD—ovarian cancer	1.57e-05	0.000253	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CG—ovarian cancer	1.54e-05	0.000248	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPP2R1A—ovarian cancer	1.54e-05	0.000247	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—ovarian cancer	1.53e-05	0.000247	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PARP1—ovarian cancer	1.52e-05	0.000245	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—ovarian cancer	1.46e-05	0.000236	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6ST—ovarian cancer	1.46e-05	0.000234	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCB1—ovarian cancer	1.43e-05	0.00023	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TYMS—ovarian cancer	1.4e-05	0.000226	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CG—ovarian cancer	1.4e-05	0.000225	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—ovarian cancer	1.4e-05	0.000225	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CB—ovarian cancer	1.37e-05	0.00022	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CD—ovarian cancer	1.35e-05	0.000218	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—ovarian cancer	1.35e-05	0.000218	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—YAP1—ovarian cancer	1.31e-05	0.000211	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PPP2R1A—ovarian cancer	1.23e-05	0.000199	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CD—ovarian cancer	1.23e-05	0.000198	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—ovarian cancer	1.18e-05	0.00019	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CB—ovarian cancer	1.18e-05	0.00019	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—ovarian cancer	1.13e-05	0.000183	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CAV1—ovarian cancer	1.13e-05	0.000182	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—ovarian cancer	1.08e-05	0.000175	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CB—ovarian cancer	1.07e-05	0.000173	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FASN—ovarian cancer	1.07e-05	0.000172	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.05e-05	0.000169	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—ovarian cancer	1.03e-05	0.000166	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CG—ovarian cancer	1.03e-05	0.000166	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.01e-05	0.000163	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CA—ovarian cancer	9.85e-06	0.000159	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—ovarian cancer	9.84e-06	0.000159	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TERT—ovarian cancer	9.8e-06	0.000158	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	9.71e-06	0.000156	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CAV1—ovarian cancer	9.07e-06	0.000146	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CD—ovarian cancer	9.03e-06	0.000146	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ESR1—ovarian cancer	8.74e-06	0.000141	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	8.61e-06	0.000139	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6ST—ovarian cancer	8.6e-06	0.000138	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CA—ovarian cancer	8.34e-06	0.000134	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CG—ovarian cancer	8.26e-06	0.000133	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APC—ovarian cancer	8.26e-06	0.000133	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—ovarian cancer	8.26e-06	0.000133	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—ovarian cancer	8.05e-06	0.00013	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCB1—ovarian cancer	7.99e-06	0.000129	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK3—ovarian cancer	7.91e-06	0.000127	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CB—ovarian cancer	7.87e-06	0.000127	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TYMS—ovarian cancer	7.85e-06	0.000126	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK1—ovarian cancer	7.53e-06	0.000121	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—ovarian cancer	7.53e-06	0.000121	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CD—ovarian cancer	7.26e-06	0.000117	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CA—ovarian cancer	7.19e-06	0.000116	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—ovarian cancer	7.11e-06	0.000115	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—ovarian cancer	6.81e-06	0.00011	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—ovarian cancer	6.8e-06	0.00011	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	6.53e-06	0.000105	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—ovarian cancer	6.41e-06	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MTOR—ovarian cancer	6.33e-06	0.000102	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	6.33e-06	0.000102	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CAV1—ovarian cancer	6.33e-06	0.000102	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—ovarian cancer	6.08e-06	9.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—ovarian cancer	6.04e-06	9.73e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	5.94e-06	9.57e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	5.88e-06	9.46e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—ovarian cancer	5.82e-06	9.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—ovarian cancer	5.81e-06	9.36e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—ovarian cancer	5.78e-06	9.32e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	5.76e-06	9.28e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—ovarian cancer	5.67e-06	9.13e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	5.61e-06	9.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—ovarian cancer	5.5e-06	8.86e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—ovarian cancer	5.47e-06	8.81e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	5.34e-06	8.59e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.07e-06	8.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	4.94e-06	7.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—ovarian cancer	4.89e-06	7.88e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—ovarian cancer	4.88e-06	7.86e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CA—ovarian cancer	4.8e-06	7.73e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	4.67e-06	7.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—ovarian cancer	4.54e-06	7.32e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	4.45e-06	7.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—ovarian cancer	4.45e-06	7.16e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.42e-06	7.11e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—ovarian cancer	4.2e-06	6.76e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—ovarian cancer	3.92e-06	6.32e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	3.86e-06	6.22e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—ovarian cancer	3.82e-06	6.15e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—ovarian cancer	3.73e-06	6.01e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—ovarian cancer	3.57e-06	5.75e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—ovarian cancer	3.42e-06	5.5e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—ovarian cancer	3.15e-06	5.08e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.69e-06	4.34e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—ovarian cancer	2.2e-06	3.54e-05	CbGpPWpGaD
